{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:09:31Z","timestamp":1791223771676,"version":"4.1.0"},"reference-count":43,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2002,6,1]],"date-time":"2002-06-01T00:00:00Z","timestamp":1022889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2002,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Micafungin (FK463) is an echinocandin that demonstrates potent in vitro antifungal activities against\n            <jats:italic>Candida<\/jats:italic>\n            and\n            <jats:italic>Aspergillus<\/jats:italic>\n            species. However, little is known about its comparative antifungal activities in persistently neutropenic hosts. We therefore investigated the plasma micafungin pharmacokinetics and antifungal activities of micafungin against experimental disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. The groups with disseminated candidiasis studied consisted of untreated controls (UCs); rabbits treated with desoxycholate amphotericin B (DAMB) at 1 mg\/kg of body weight\/day; or rabbits treated with micafungin at 0.25, 0.5, 1, and 2 mg\/kg\/day intravenously. Compared with the UCs, rabbits treated with micafungin or DAMB showed significant dosage-dependent clearance of\n            <jats:italic>Candida albicans<\/jats:italic>\n            from the liver, spleen, kidney, brain, eye, lung, and vena cava. These in vivo findings correlated with the results of in vitro time-kill assays that demonstrated that micafungin has concentration-dependent fungicidal activity. The groups with invasive pulmonary aspergillosis studied consisted of UCs; rabbits treated with DAMB; rabbits treated with liposomal amphotericin B (LAMB) at 5 mg\/kg\/day; and rabbits treated with micafungin at 0.5, 1, and 2 mg\/kg\/day. In comparison to the significant micafungin dosage-dependent reduction of the residual burden (in log CFU per gram) of\n            <jats:italic>C. albicans<\/jats:italic>\n            in tissue, micafungin-treated rabbits with invasive pulmonary aspergillosis had no reduction in the concentration of\n            <jats:italic>Aspergillus fumigatus<\/jats:italic>\n            in tissue. DAMB and LAMB significantly reduced the burdens of\n            <jats:italic>C. albicans<\/jats:italic>\n            and\n            <jats:italic>A. fumigatus<\/jats:italic>\n            in tissues (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.01). Persistent galactomannan antigenemia in micafungin-treated rabbits correlated with the presence of an elevated burden of\n            <jats:italic>A. fumigatus<\/jats:italic>\n            in pulmonary tissue. By comparison, DAMB- and LAMB-treated animals had significantly reduced circulating galactomannan antigen levels. Despite a lack of clearance of\n            <jats:italic>A. fumigatus<\/jats:italic>\n            from the lungs, there was a significant improvement in the rate of survival (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.001) and a reduction in the level of pulmonary infarction (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.05) in micafungin-treated rabbits. In summary, micafungin demonstrated concentration-dependent and dosage-dependent clearance of\n            <jats:italic>C. albicans<\/jats:italic>\n            from persistently neutropenic rabbits with disseminated candidiasis but not of\n            <jats:italic>A. fumigatus<\/jats:italic>\n            from persistently neutropenic rabbits with invasive pulmonary aspergillosis.\n          <\/jats:p>","DOI":"10.1128\/aac.46.6.1857-1869.2002","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T10:09:29Z","timestamp":1027764569000},"page":"1857-1869","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":160,"title":["Comparative Antifungal Activities and Plasma Pharmacokinetics of Micafungin (FK463) against Disseminated Candidiasis and Invasive Pulmonary Aspergillosis in Persistently Neutropenic Rabbits"],"prefix":"10.1128","volume":"46","author":[{"given":"Vidmantas","family":"Petraitis","sequence":"first","affiliation":[{"name":"Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruta","family":"Petraitiene","sequence":"additional","affiliation":[{"name":"Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas H.","family":"Groll","sequence":"additional","affiliation":[{"name":"Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Roussillon","sequence":"additional","affiliation":[{"name":"Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Hemmings","sequence":"additional","affiliation":[{"name":"Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caron A.","family":"Lyman","sequence":"additional","affiliation":[{"name":"Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tin","family":"Sein","sequence":"additional","affiliation":[{"name":"Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Bacher","sequence":"additional","affiliation":[{"name":"Warren Grant Magnuson Clinical Center and Surgery Service, Veterinary Resources Program, Office of Research Services, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihor","family":"Bekersky","sequence":"additional","affiliation":[{"name":"Fujisawa Healthcare, Inc., Deerfield, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Walsh","sequence":"additional","affiliation":[{"name":"Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/14.Supplement_1.S43"},{"key":"e_1_3_1_3_2","first-page":"172","volume":"1","year":"1999","unstructured":"Anonymous. 1999. FK 463. Drugs Res. Dev.1:172-173.","journal-title":"Drugs Res. Dev."},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.67.1.307"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(00)00236-4"},{"key":"e_1_3_1_6_2","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1634\/theoncologist.5-2-120","volume":"5","year":"2000","unstructured":"Chiou, C. C., A. H. Groll, and T. J. Walsh. 2000. New drugs and novel targets for treatment of invasive fungal infections in patients with cancer. Oncologist5:120-135.","journal-title":"Oncologist"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1139\/m91-108"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/169.2.356"},{"key":"e_1_3_1_9_2","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/clind\/15.6.1003","volume":"15","year":"1992","unstructured":"Francis, P., and T. J. Walsh. 1992. The evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Rev. Infect. Dis.15:1003-1018.","journal-title":"Rev. Infect. Dis."},{"key":"e_1_3_1_10_2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1517\/13543784.7.2.175","volume":"7","year":"1998","unstructured":"Frosco, M. B., and J. F. Barret. 1998. Importance of antifungal drug-resistance: clinical significance and need for novel therapy. Expert Opin. Investig. Drugs7:175-197.","journal-title":"Expert Opin. Investig. Drugs"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.10.2.269"},{"key":"e_1_3_1_12_2","doi-asserted-by":"crossref","unstructured":"Gibaldi M. and D. Perrier. 1982. Pharmacokinetics 2nd ed. p. 455-459. Marcel Dekker Inc. New York N.Y.","DOI":"10.1201\/b14095"},{"key":"e_1_3_1_13_2","unstructured":"Groll A. A. Glasmacher J. Gudrun G. Maschmeyer and T. J. Walsh. Clinical pharmacology of antifungal agents. Infect. Dis. Clin. N. Am. in press."},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.12.3322-3327.2001"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-4453(96)92700-0"},{"key":"e_1_3_1_16_2","first-page":"405","volume":"2","year":"2000","unstructured":"Groll, A. H., and T. J. Walsh. 2000. FK-463. Curr. Opin. Antifungal Infective Investig. Drugs2:405-412.","journal-title":"Drugs"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.3.614-618.2000"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.6.1387"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.7.1480"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.4.713"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.6.1728-1730.2000"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.3.619-621.2000"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.3.485"},{"key":"e_1_3_1_24_2","unstructured":"National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_1_25_2","unstructured":"National Committee for Clinical Laboratory Standards. 1998. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Proposed standard M38-P. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_1_26_2","unstructured":"National Research Council Committee on the Care and Use of Laboratory Animals Institute of Laboratory Animal Resources Commission on Life Sciences. 1996. Guide for the care and use of laboratory animals. National Academy Press Washington D.C."},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(95)00010-0"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920601)69:11<2653::AID-CNCR2820691106>3.0.CO;2-8"},{"key":"e_1_3_1_29_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1200\/JCO.1991.9.1.77","volume":"9","year":"1991","unstructured":"Pannuti, C. S., R. D. Gingrich, M. A. Pfaller, and R. P. Wenzel. 1991. Nosocomial pneumonia in adult patients undergoing bone marrow transplantation: a 9-year study. J. Clin. Oncol.9:77-84.","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1995.00430110089009"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.1.1"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/28.suppl_B.73"},{"key":"e_1_3_1_33_2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/00325481.1990.11716368","volume":"88","year":"1990","unstructured":"Sarosi, G. A. 1990. Amphotericin B: still the \u2032gold standard\u2019 for antifungal therapy. Postgrad. Med.88:151-152, 155-161, 165-166.","journal-title":"Postgrad. Med."},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.33.2.497-500.1995"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.60.6.2237-2245.1992"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.1.57-62.2000"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.52.674"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.53.1175"},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.1086\/516480"},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.25.5.931-932.1987"},{"key":"e_1_3_1_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5520(05)70303-2"},{"key":"e_1_3_1_42_2","first-page":"467","volume":"38","year":"1988","unstructured":"Walsh, T. J., P. Bacher, and P. A. Pizzo. 1988. Chronic silastic central venous catheterization for induction, maintenance, and support of persistent granulocytopenia in rabbits. Lab. Anim. Med.38:467-470.","journal-title":"Lab. Anim. Med."},{"key":"e_1_3_1_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.7.1321"},{"key":"e_1_3_1_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01117450"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.46.6.1857-1869.2002","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.46.6.1857-1869.2002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T17:53:54Z","timestamp":1645466034000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.46.6.1857-1869.2002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,6]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2002,6]]}},"alternative-id":["10.1128\/AAC.46.6.1857-1869.2002"],"URL":"https:\/\/doi.org\/10.1128\/aac.46.6.1857-1869.2002","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,6]]},"assertion":[{"value":"2001-08-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-02-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-06-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}